135363-97-2

Upstream product

• 135363-95-0 ((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-hydroxy-acetic acid methyl ester 
• 135363-92-7 1-((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-prop-2-en-1-ol 
• 201230-82-2 carbon monoxide 
• 135363-94-9 ((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-(tert-butyl-dimethyl-silanyloxy)-acetic acid methyl ester 
• 147239-40-5 3-((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-propane-1,2-diol 
• 147239-41-6 ((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-(tert-butyl-dimethyl-silanyloxy)-acetaldehyde 
• 135363-93-8 [1-((2R,3R,4S)-3,4-Bis-benzyloxymethyl-oxetan-2-yl)-allyloxy]-tert-butyl-dimethyl-silane 

Relevant academic research and scientific papers

The first asymmetric ring-expansion carbonylation of meso-epoxides

The first asymmetric ring-expansion carbonylation of meso-epoxides to β-lactones is reported. Two structurally diverse chiral Cr(iii) chloro complexes in conjunction with Co2(CO)8 were shown to be competent catalytic systems for this

Synthetic studies on oxetanocin analogs: Synthesis of oxetanosyl c-nucleoside, 2-deoxy-2-hydroxymethyl-β-D-erythrooxetanosyl maleimide

Synthesis of oxetanosyl C-nucleoside similar to showdomycin, 2-deoxy-2-hydroxy-methyl-β-D-erythrooxetanosyl maleimide has successfully been carried out starting from the potent intermediate of oxetanocin synthesis.